Rigel Pharmaceuticals (RIGL) Assets Average (2016 - 2025)
Rigel Pharmaceuticals has reported Assets Average over the past 15 years, most recently at $378.1 million for Q4 2025.
- Quarterly results put Assets Average at $378.1 million for Q4 2025, up 149.22% from a year ago — trailing twelve months through Dec 2025 was $378.1 million (up 149.22% YoY), and the annual figure for FY2025 was $338.8 million, up 140.96%.
- Assets Average for Q4 2025 was $378.1 million at Rigel Pharmaceuticals, up from $224.6 million in the prior quarter.
- Over the last five years, Assets Average for RIGL hit a ceiling of $378.1 million in Q4 2025 and a floor of $116.2 million in Q3 2023.
- Median Assets Average over the past 5 years was $145.1 million (2022), compared with a mean of $163.4 million.
- Biggest five-year swings in Assets Average: plummeted 37.23% in 2022 and later skyrocketed 149.22% in 2025.
- Rigel Pharmaceuticals' Assets Average stood at $176.9 million in 2021, then fell by 29.38% to $124.9 million in 2022, then fell by 6.94% to $116.3 million in 2023, then soared by 30.46% to $151.7 million in 2024, then skyrocketed by 149.22% to $378.1 million in 2025.
- The last three reported values for Assets Average were $378.1 million (Q4 2025), $224.6 million (Q3 2025), and $191.4 million (Q2 2025) per Business Quant data.